

References

I-9049

1. Vyjuvek prescribing information. Krystal Biotech, Inc. May 2023.
2. Fine JD. Inherited epidermolysis bullosa. Orphanet J Rare Dis. 2010 May 28;5:12. doi: 10.1186/1750-1172-5-12
3. gov Identifier: NCT03536143. A phase I/II study of KB103, a topical HSV1-COL7, on DEB patients. Updated January 31, 2023. <https://clinicaltrials.gov/ct2/show/NCT03536143?cond=NCT03536143&draw=2&rank=1>.
4. Gurevich I, Agarwal P, Zhang P, et al. In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial. Nat Med. 2022;28(4):780-788. doi:10.1038/s41591-022-01737-y
5. Marinovich, M. Peter, Gonzalez, Mercedes E., et. al. GEM-3: A Phase 3 Study of Beremagene Geperpavec (B-VEC), an Investigational, Topical Gene Therapy, for the Treatment of Dystrophic Epidermolysis Bullosa (DEB). <https://ir.krystalbio.com/static-files/bb74b04e-7e3d-44f8-afda-5469a3cf16b4>.
6. Guide, Sharon V, Gonzalez, Mercedes E., et al. Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa. N Engl J Med. 2022 Dec 15;387(24):2211-2219. doi: 10.1056/NEJMoa2206663.
7. Marinovich, M. Peter, Gonzalez, Mercedes E., et al. GEM-3: Phase 3 Safety and Immunogenicity Results of Beremagene Geperpavec (B-VEC), an Investigational, Topical Gene Therapy for Dystrophic Epidermolysis Bullosa (DEB). <https://ir.krystalbio.com/static-files/52bf3182-9694-43c1-9e6b-0af5d4952a91>.